Search Results 111-120 of 17053 for coronavirus

  1. A Study to Evaluate the Pandemic Response Optimizing Technology and Ethics for Coronavirus Teams Implementing Novel Genetics - Mayo Clinic

    A Study to Evaluate the Pandemic Response Optimizing Technology and Ethics for Coronavirus Teams Implementing Novel Genetics · Overview · Participation ...

  2. Sars-cov-2 (covid-19) vaccine, mrna-lnp, spike protein (pfizer) (intramuscular route) - Mayo Clinic

    SARS-CoV-2 (COVID-19) vaccine is used to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

  3. Mayo Clinic president and CEO participates in the Coronavirus Task Force meeting

    Gianrico Farrugia, M.D., president and CEO of Mayo Clinic, attended a meeting on Wednesday, March 11, convened by the White House Coronavirus Task Force.

  4. Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment (enrollment by invitation only) - Mayo Clinic

    Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard ...

  5. Respiratory syncytial virus (RSV) - Symptoms & causes - Mayo Clinic

    Because RSV and coronavirus disease 2019 (COVID-19) are both types of respiratory viruses, some symptoms of RSV and COVID-19 can be similar. In children ...

  6. Sars-cov-2 (covid-19) vaccine, protein subunit, adjuvanted (novavax) (intramuscular route) - Mayo Clinic

    SARS-CoV-2 (COVID-19) vaccine is used to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

  7. Antibodies against COVID (enrolling by invitation) - Mayo Clinic

    About this study. The study is being done to identify how many Healthcare workers develop antibodies against the SARS-CoV 2 virus over a 6 month period ...

  8. Vaccine requirements and vaccine research highlights

    Coronavirus vaccine development: From SARS and MERS to COVID-19. Journal of Biomedical Science. 2020; doi:10.1186/s12929-020-00695-2. Dolgin E. The tangled ...

  9. Molnupiravir (oral route) - Mayo Clinic

    Molnupiravir is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in non-hospitalized patients who are at high risk for progression to ...

  10. Video: SCAD and COVID-19 - Spontaneous Coronary Artery Dissection (SCAD) Research Program

    Watch a video from Mayo Clinic's Spontaneous Coronary Artery Dissection (SCAD) Research Program about SCAD and the novel coronavirus that causes COVID-19.